All In Biotech

Drug Trial Radar · NCT06107205

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

A Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Nov 7, 2023

Primary completion

Dec 14, 2023

Study completion Dec 14, 2023

Sponsor

Sponsor type
Industry
First posted
Oct 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions.The objective is To characterize the bioequivalence、safety and tolerability of TTYP01 tablets and Radicava® injection or Radicava ORS®in healthy adult subjects under fasted conditions.In this study, 30 healthy adult subjects will receive TTYP01, or Radicava, orRadicava ORS in each period according to the randomization sequence.

Conditions

  • Healthy Adult Subjects

Interventions

  • TTYP01Drug

    1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)

  • RadicavaDrug

    1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)

  • Radicava ORSDrug

    1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK Parameters-Area under the plasma concentration-time curve (AUC0-inf) from time 0 extrapolated to infinity of unchanged edaravone after TTYP01, Radicava and Radicava ORS administrationTime frame: up to 48 hours each postdose
  2. PK Parameters- AUC from time 0 to the last measurable non-zero concentration(AUC0-t)of unchanged edaravone after TTYP01, Radicava and Radicava ORS administrationTime frame: up to 48 hours each postdose
  3. PK Parameters - Maximum observed concentration (Cmax) of unchanged edaravone after TTYP01, Radicava and Radicava ORS administrationTime frame: up to 48 hours each postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Phase Services

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.